Literature DB >> 9476990

Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus.

S Helsley1, D Fiorella, R A Rabin, J C Winter.   

Abstract

In the present investigation, the ability of two known hallucinogens, lysergic acid dimethylamide (LSD) and (-)-2,5-dimethoxy-4-methyl-amphetamine (DOM), to substitute for the ibogaine-induced discriminative stimulus (10 mg/kg I.P., 60 min presession) was assessed in Fischer-344 rats. In these subjects, intermediate levels of generalization were observed to both agents (LSD, 63%; DOM, 66.4%). This intermediate generalization was completely blocked by pretreatment with the 5-HT2A antagonist pirenpirone, suggesting that the ibogaine-like effects of these agents are mediated by the 5-HT2A receptor. However, pirenpirone did not antagonize ibogaine itself, nor did it antagonize the ibogaine-like effects of harmaline and 12-hydroxyibogamine (noribogaine). To further evaluate the serotonergic properties of ibogaine, in vivo protection assays and in vitro binding assays were employed. Micromolar 5-HT2A affinity was observed with ibogaine (92.5 microM), 12-hydroxyibogamine (34.5 microM), and harmaline (42.5 microM). Despite the apparently low affinity of these agents, both ibogaine and harmaline, but not 12-hydroxyibogamine, produced significant protection from receptor alkylation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) when given 60 min prior to this alkylating agent. The results of these studies suggest that although ibogaine may produce some of its effects via interactions with 5-HT2A receptors, these do not appear to be essential to the ibogaine-induced discriminative stimulus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9476990     DOI: 10.1016/s0091-3057(97)00451-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine.

Authors:  Nicholas MacInnes; Sheila L Handley
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Psilocybin-induced stimulus control in the rat.

Authors:  J C Winter; K C Rice; D J Amorosi; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2007-06-22       Impact factor: 3.533

4.  EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.

Authors:  Joaquín González; Matias Cavelli; Santiago Castro-Zaballa; Alejandra Mondino; Adriano B L Tort; Nicolás Rubido; Ignacio Carrera; Pablo Torterolo
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-11

5.  Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.

Authors:  Adrian Handforth
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-12

6.  Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.

Authors:  Joaquín González; José P Prieto; Paola Rodríguez; Matías Cavelli; Luciana Benedetto; Alejandra Mondino; Mariana Pazos; Gustavo Seoane; Ignacio Carrera; Cecilia Scorza; Pablo Torterolo
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.